The homeodomain transcription factor MEIS1 triggers chemokine expression and is involved in CD8+ T‐lymphocyte infiltration in early stage ovarian cancer

Karapetsas, Athanasios; Tokamani, Maria; Evangelou, Christos; Sandaltzopoulos, Raphael

doi:10.1002/mc.22840

Cited by 14 publications

(15 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Also, NPTX2 expression was negatively correlated with CD8A, GZMB, and IFNG. Emerging evidence suggests that CCL4 potentially drives the recruitment of CD8 + T cells 40–42 . Additionally, we found that the level of CCL4 was elevated via siRNA‐induced NPTX2 silencing.…”

Section: Discussionmentioning

confidence: 55%

A comprehensive analysis of immune infiltration in the tumor microenvironment of osteosarcoma

et al. 2021

View full text Add to dashboard Cite

Background Even though immunotherapy has been an effective treatment for solid tumors, its efficacy in osteosarcoma remains sub‐optimal. It is therefore imperative to understand the complex tumor microenvironment (TME) of osteosarcoma to facilitate the development of immunotherapies against this cancer. Methods The mRNA expression profiles of osteosarcoma tissues were downloaded from The Cancer Genome Atlas (TCGA) database. Next, the ssGSEA, MCP‐counter, CIBERSORT, and Xcell algorithm analyses were performed to characterize the tumor microenvironment of osteosarcoma tissues. The tumor tissues were divided into inflammatory and non‐inflammatory. A comprehensive assessment of immune cell infiltration in osteosarcoma tissues was then performed. Sub‐group analysis of immune cell infiltration between men and women patients with osteosarcoma was also carried out. Results The results revealed that the infiltration of immune cells including activated B cell, activated CD8 T cell, CD56dim natural killer cell, and cytotoxic lymphocytes cells, in osteosarcoma tissues was higher in male than in female patients. Based on the infiltration profile of different immune cells, the osteosarcoma tissues were grouped into four clusters. The four clusters were further divided into hot and cold tumors. The differently expressed genes (DEGs) between cold and hot tumors were mainly associated with the activation and regulation of immune response. Additionally, a neuronal pentraxin (NPTX2) expression which was upregulated in cold tumors was found to be negatively correlated with the expression of CD8a Molecule (CD8A), Granzyme B (GZMB), and Interferon Gamma (IFNG). NPTX2 decreased CCL4 secretion. Knockdown of NPTX2 in osteosarcoma cells inhibited tumor growth and increased tumor cell apoptosis. Moreover, a prognosis prediction model of osteosarcoma was constructed and validated in patients receiving immunotherapy using external data. Conclusions To the best of our knowledge, this is the first study to characterize the infiltration of immune cells in osteosarcoma tissues from patients receiving immune infiltration therapy.

show abstract

Section: Discussionmentioning

confidence: 55%

A comprehensive analysis of immune infiltration in the tumor microenvironment of osteosarcoma

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Further, it was not clear why serum levels of CXCL7 were higher in the male than in the female group. We speculate that CXCL7 may be influenced or regulated by key factors such as MEIS1 (Myeloid Ecotropic Viral Integration Site 1) and Galectin-3 (31, 32). If possible, we plan to measure these relevant indices in the future.…”

Section: Discussionmentioning

confidence: 99%

Serum Chemokine CXCL7 as a Diagnostic Biomarker for Colorectal Cancer

Zhang

Tian

et al. 2019

Front. Oncol.

View full text Add to dashboard Cite

Identification of effective biomarkers is crucial for monitoring the treatment and remission of colorectal cancer (CRC) and improving survival. It is particularly important to diagnose CRC before the tumor metastasizes (stage I–II disease) where possible, to provide the greatest opportunity for patient recovery. Here, we evaluated the clinical value of serum chemokine (C-X-C) ligand 7 (CXCL7) concentration as a biomarker for CRC diagnosis. An enzyme-linked immunosorbent assay was used to measure CXCL7 concentration in 560 serum samples from patients with CRC and controls. Logistic regression and receiver operating characteristic (ROC) curve analysis was used to assess the diagnostic efficacy and build mathematical diagnostic models. The concentration of CXCL7 in the CRC group was significantly higher than that in the control group (P < 0.001), with an area under the ROC curve (AUC) value of 0.862 [95% confidence interval (CI): 0.831–0.890]. Further, the AUC of a regression model including the markers carcinoembryonic antigen (CEA), carbohydrate antigen 19-9 (CA19-9), and carbohydrate antigen 125 (CA125), along with CXCL7, was 0.933 (95% CI: 0.909–0.952). For stage I–II tumors, CXCL7 had the highest AUC (0.823, 95% CI: 0.783–0.858) among the four individual biomarkers. The AUC value for combination model analysis of samples from patients with stage I–II tumors was 0.904 (95% CI: 0.872–0.930), with a sensitivity of 82.76% and a specificity of 87.14%, and an optimal cut-off value of 2.66. AUC values for application of the regression model in subgroup analysis were 0.947 (0.917–0.968) and 0.919 (0.874–0.951) for males and females, respectively. These results suggest that CXCL7 has potential as a serum diagnostic biomarker for detection of CRC. Importantly, the combination of CXCL7, CEA, CA125, and CA19-9 may facilitate diagnosis of CRC with relatively high sensitivity and specificity.Clinical Trial Registration Number: LS2017001.

show abstract

“…For example, Lin's study showed ATXN2L upregulated by epidermal growth factor promotes gastric cancer cell invasiveness (25). Deregulation of MEIS1 had been reported in cancers like prostate cancer (26), ovarian cancer (27), lung cancer (28). MEIS1 transcriptionally regulated the expression of hypoxic tumor markers, namely Hif-1a and Hif-2a, which had crucial roles in tumorigenesis (29).…”

Section: Discussionmentioning

confidence: 99%

Prognostic Alternative mRNA Splicing in Adrenocortical Carcinoma

Liang

Sun

2021

Front. Endocrinol.

View full text Add to dashboard Cite

BackgroundThis paper aims to identify alternative RNA splicing landscape and its prognostic value in adrenocortical carcinoma.MethodsThe alternative splicing events data with corresponding clinical information data of 79 ACC patients were obtained from the Cancer Genome Atlas and SpliceSeq package. Prognosis-associated AS events by using univariate Cox regression analysis were selected. Gene functional enrichment analysis demonstrated the potential pathways enriched by survival-associated AS. Prognosis-related splicing events were submitted to develop moderate predictors using Lasso regression model.ResultsOne thousand five survival-associated alternative splicing events were identified. The prognostic genes included ATXN2L, MEIS1, IKBKB, COX4I1. Functional enrichment analysis suggested that prognostic splicing events are associated with Wnt signaling pathway. A prediction model including 12 alternative splicing events was constructed by Lasso regression using train set. ROC analysis showed good performance of the prediction model in test set. Then, a nomogram integrating the clinical-pathological factors and riskscore was constructed for predicting 1‐ and 3‐year survival rate.ConclusionOur data provide a comprehensive bioinformatics analysis of AS events in ACC, providing biomarkers for disease progression and a potentially rich source of novel therapeutic targets.

show abstract

The homeodomain transcription factor MEIS1 triggers chemokine expression and is involved in CD8+ T‐lymphocyte infiltration in early stage ovarian cancer

Cited by 14 publications

References 48 publications

A comprehensive analysis of immune infiltration in the tumor microenvironment of osteosarcoma

A comprehensive analysis of immune infiltration in the tumor microenvironment of osteosarcoma

Serum Chemokine CXCL7 as a Diagnostic Biomarker for Colorectal Cancer

Prognostic Alternative mRNA Splicing in Adrenocortical Carcinoma

Contact Info

Product

Resources

About